BioWorld

July 26, 2004

View Archived Issues

Aranesp, Enbrel, Neulasta Sales Drive Amgen To Beat Estimates

Amgen Inc. turned in second-quarter adjusted earnings per share of 62 cents, topping consensus estimates and surging 27 percent higher than a year ago. (BioWorld Today) Read More

Gene Logic Acquires Discovery Program, Team From Millennium

Read More

Specialty Pharma Firm Auxilium Raises $41.25M In Initial Offering

Read More

Santarus Gets $57M In Follow-On Following Approval Of Rapinex

Read More

Hudson Health Gains Listing Via Reverse Merger, Raises $8M

Read More

Tapestry Calls On Supratek To Help Develop New Formulations

Read More

Other News To Note

Read More